Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NVCT

Nuvectis Pharma Inc

Dec 13 • 03:22PM ET

4.60

Dollar change -0.04
Percentage change -0.86	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX AMGN GILD BMY REGN BIIB MRNA ILMN INCY NBIX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	53.78%	Shs Outstand	18.99M	Perf Week	-5.54%
Market Cap	88.88M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	0.19%	Shs Float	8.93M	Perf Month	-56.89%
Income	-19.37M	PEG	-	EPS next Q	-0.25	Inst Own	5.46%	Short Float	15.90%	Perf Quarter	-28.12%
Sales	0.00M	P/S	-	EPS this Y	29.60%	Inst Trans	-36.51%	Short Ratio	8.25	Perf Half Y	-32.05%
Book/sh	0.58	P/B	7.95	EPS next Y	5.96%	ROA	-97.93%	Short Interest	1.42M	Perf Year	-45.75%
Cash/sh	0.89	P/C	5.18	EPS next 5Y	-	ROE	-140.00%	52W Range	4.52 - 12.10	Perf YTD	-44.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-176.27%	52W High	-61.98%	Beta	0.21
Dividend TTM	-	Quick Ratio	2.74	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.77%	ATR (14)	0.60
Dividend Ex-Date	-	Current Ratio	2.74	EPS Y/Y TTM	22.97%	Oper. Margin	-	RSI (14)	36.17	Volatility	6.22% 10.22%
Employees	13	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	34.01%	Payout	-	Rel Volume	0.52	Prev Close	4.64
Sales Surprise	-	EPS Surprise	4.91%	Sales Q/Q	-	Earnings	Nov 05 BMO	Avg Volume	172.09K	Price	4.60
SMA20	-6.76%	SMA50	-29.86%	SMA200	-33.68%	Trades		Volume	80,816	Change	-0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-22	Initiated	Ladenburg Thalmann	Buy	$21

Dec-10-24 08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium (GlobeNewswire)
Nov-25-24 09:55AM	Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-15-24 07:45AM	Nuvectis Pharma reports data from Phase 1b study of NXP800 (TipRanks) -13.61%
Nov-14-24 02:23PM	Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug (Benzinga) -46.30%
07:00AM	Loading…
07:00AM	Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire)
Nov-13-24 08:50AM	Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-07-24 09:55AM	Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know (Zacks)
Nov-05-24 07:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +17.75%
Oct-28-24 08:21AM	PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update (Business Wire) -10.50%
Oct-23-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.33%
Oct-07-24 08:00AM	Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-16-24 07:15AM	PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch (Business Wire)
Sep-05-24 08:00AM	Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.81%
Aug-30-24 06:52AM	Nuvectis NXP800 gains FDA ODD for cancer treatment (Pharmaceutical Technology)
08:00AM	Loading…
Aug-29-24 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (GlobeNewswire)
Aug-06-24 08:28AM	Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.83%
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace) +5.96%
May-24-24 09:55AM	Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? (Zacks) -7.04%
May-16-24 08:30AM	Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-24 09:06PM	Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes (GuruFocus.com) -10.57%
01:53PM	NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-08-24 08:30AM	Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines (GlobeNewswire)
Apr-02-24 04:30PM	5 Healthcare Stocks to Buy for 2024 (InvestorPlace)
Mar-19-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting (GlobeNewswire) -16.08%
Mar-15-24 08:00AM	Nuvectis Pharma to Present at the 36th Annual Roth Conference (GlobeNewswire) +20.22%
Mar-14-24 09:00AM	Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire) -5.08%
Mar-05-24 11:52PM	NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 (InvestorPlace)
08:31AM	Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	Loading…
08:00AM	Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-09-24 08:32AM	Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-03-24 08:00AM	Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:00AM	Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma (GlobeNewswire)
Nov-08-23 08:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -7.83%
Oct-24-23 08:00AM	Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (GlobeNewswire)
Oct-16-23 09:35AM	Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT) (Zacks) +15.87%
Sep-25-23 07:30PM	Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation (GlobeNewswire)
Sep-21-23 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 (GlobeNewswire)
Sep-12-23 08:00AM	Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial (GlobeNewswire)
Sep-06-23 08:00AM	Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 (GlobeNewswire)
Sep-01-23 08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 08:00AM	Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research)
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research) +7.41%
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
06:51AM	Daily Vickers Top Buyers & Sellers for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
07:58AM	Daily Vickers Top Buyers & Sellers for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research) +5.18%
07:23AM	Daily Vickers Top Buyers & Sellers for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
06:55AM	Daily Vickers Top Buyers & Sellers for 07/20/2023 (Argus Research)
Jul-19-23 07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
07:10AM	Daily Vickers Top Buyers & Sellers for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research)
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research)
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research)
06:50AM	Daily Vickers Top Buyers & Sellers for 07/14/2023 (Argus Research)
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research)
07:02AM	Daily Vickers Top Buyers & Sellers for 07/13/2023 (Argus Research)
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research)
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
06:08AM	Daily Vickers Top Buyers & Sellers for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research) +5.97%
06:56AM	Daily Vickers Top Buyers & Sellers for 07/10/2023 (Argus Research)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research)
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research)
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research)
Jun-28-23 07:13AM	Daily Vickers Top Buyers & Sellers for 06/28/2023 (Argus Research)
06:58AM	Daily Vickers Top Insider Picks for 06/28/2023 (Argus Research)
Jun-27-23 06:46AM	Daily Vickers Top Insider Picks for 06/27/2023 (Argus Research)
06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-26-23 06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-21-23 07:20AM	Daily Vickers Top Buyers & Sellers for 06/21/2023 (Argus Research)
Jun-20-23 08:00AM	Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
06:35AM	Daily Vickers Top Buyers & Sellers for 06/20/2023 (Argus Research)
Jun-18-23 08:03AM	Charles Mosseri-Marlio Buys 1.3% More Nuvectis Pharma Shares \ (Simply Wall St.)
Jun-05-23 08:50AM	Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going (Zacks)
Jun-01-23 04:48AM	Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree (Zacks)
May-31-23 06:22AM	3 Best Breakout Stocks Worth Buying for Superlative Returns (Zacks)
May-19-23 08:50AM	Here's What Could Help Nuvectis Pharma, Inc. (NVCT) Maintain Its Recent Price Strength (Zacks)
May-15-23 09:55AM	Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a Bet (Zacks) +6.19%
08:00AM	Nuvectis Pharma Announces FDA Clearance of NXP900 IND (GlobeNewswire)
May-10-23 08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Poradosu Enrique	Chief Science & Business Off	Nov 19 '24	Buy	4.99	2,000	9,980	1,506,319	Nov 20 08:30 AM
BENTSUR RON	Chairman & CEO	Nov 15 '24	Buy	4.92	20,000	98,400	3,266,424	Nov 18 08:30 AM
Carson Michael J.	Vice President, Finance	Nov 07 '24	Sale	8.16	2,755	22,478	87,918	Nov 08 03:59 PM
BENTSUR RON	Chairman & CEO	May 14 '24	Buy	6.74	1,940	13,076	3,246,424	May 15 09:16 AM
BENTSUR RON	Chairman & CEO	May 10 '24	Buy	6.40	2,000	12,800	3,244,484	May 13 08:51 AM
Poradosu Enrique	Chief Science & Business Off	May 10 '24	Buy	6.29	500	3,145	1,504,319	May 13 08:49 AM
Shemesh Shay	Chief Dev. & Ops. Officer	May 10 '24	Buy	6.32	1,113	7,034	1,493,068	May 13 08:47 AM
BENTSUR RON	Chairman & CEO	Mar 18 '24	Buy	10.29	5,000	51,450	3,242,484	Mar 19 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCT

Nuvectis Pharma Inc

Upgrade your FINVIZ experience